tiprankstipranks
Pascal Biosciences Inc (TSE:NEVI)
:NEVI

Pascal Biosciences Inc (NEVI) AI Stock Analysis

5 Followers

Top Page

TSE:NEVI

Pascal Biosciences Inc

(NEVI)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 5.2)
Rating:43Neutral
Price Target:
C$0.03
▼(-51.43% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily constrained by ongoing unprofitability and sharp gross margin compression despite improving revenue growth and a return to positive operating/free cash flow. Technically, the stock remains in a bearish trend below major moving averages with negative MACD. Valuation provides limited support given the negative P/E and lack of dividend.
Positive Factors
Accelerating Revenue Growth
Revenue acceleration into 2025 indicates expanding top-line traction and improving product or market adoption. A durable upward revenue trend supports operating leverage over time, providing a basis for margin recovery and capacity to invest in growth if management sustains execution.
Negative Factors
Persistent Net Losses
Despite improvement, continued negative net margins indicate the company has not yet reached sustainable profitability. Persistent losses erode equity and constrain reinvestment capacity, meaning profitability must improve structurally to support long-term growth without recurring capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue acceleration into 2025 indicates expanding top-line traction and improving product or market adoption. A durable upward revenue trend supports operating leverage over time, providing a basis for margin recovery and capacity to invest in growth if management sustains execution.
Read all positive factors

Pascal Biosciences Inc (NEVI) vs. iShares MSCI Canada ETF (EWC)

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description
Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevi...
How the Company Makes Money
null...

Pascal Biosciences Inc Financial Statement Overview

Summary
Results show improvement but remain weak overall: revenue growth accelerated in 2025 and losses narrowed, with operating and free cash flow turning positive. Offsetting this, profitability is still negative (negative operating and net margins), and gross margin compressed sharply in 2025, indicating meaningful cost/mix pressure and execution risk.
Income Statement
38
Negative
Balance Sheet
54
Neutral
Cash Flow
46
Neutral
BreakdownNov 2025Feb 2025Feb 2024Nov 2022Feb 2022
Income Statement
Total Revenue1.70M1.55M671.54K0.000.00
Gross Profit396.31K1.08M392.94K-8.29K-16.32K
EBITDA-32.66K-48.07K-271.56K-468.09K-1.07M
Net Income-275.07K-362.48K-399.77K-480.28K-1.09M
Balance Sheet
Total Assets1.72M2.04M2.50M18.82K155.19K
Cash, Cash Equivalents and Short-Term Investments102.17K129.54K418.52K8.37K0.00
Total Debt244.21K528.30K683.27K224.62K7.76K
Total Liabilities746.36K813.50K1.12M962.93K646.48K
Stockholders Equity968.95K1.23M1.38M-944.11K-491.30K
Cash Flow
Free Cash Flow62.10K-132.06K-390.49K-147.68K-614.93K
Operating Cash Flow62.10K-120.50K-385.35K-147.68K-614.93K
Investing Cash Flow0.00-11.56K-947.71K8.98K0.00
Financing Cash Flow-90.20K-167.65K1.76M154.84K624.08K

Pascal Biosciences Inc Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.07
Price Trends
50DMA
0.04
Negative
100DMA
0.04
Negative
200DMA
0.05
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
49.81
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Neutral. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
44
Neutral
C$1.69M-4.08-3.76%86.34%
43
Neutral
C$1.39M-7.21-21.78%-6.85%22.09%
41
Neutral
C$1.52M1.34-129.49%-98.28%76.18%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:NEVI
Pascal Biosciences Inc
0.04
-0.02
-30.00%
TSE:TAAT
TAAT Global Alternatives
0.18
-0.01
-5.41%
TSE:WIB
West Island Brands Inc
0.13
0.00
0.00%
TSE:MEAT
Modern Meat
0.12
-0.05
-28.13%
TSE:LFST
Lifeist Wellness
0.04
0.00
0.00%
TSE:MUSL
Element Nutritional Sciences Inc
0.04
-0.01
-20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026